Stock Groups

Nanobiotix Rallies After Enrolling First Patient in Head and Neck Cancer Treatment -Breaking

by Mike Robinson

[ad_1]


Sam Boughedda

Investing.com — Nanobiotix (NASDAQ) shares surged 23% after the company announced that they have enrolled their first patient for a Phase 3 trial of treatment for head-and neck cancer.

The study is designed to investigate the efficacy and safety of radiotherapy-activated NBTXR3 in high-risk, chemotherapy-ineligible elderly patients with locally advanced head and neck cancer. This trial is a continuation of the Nanobiotix Study 102 phase 1, which evaluated safety and showed early signs for efficacy.

The U.S. Food and Drug Administration has granted Fast Track designation to investigate radiotherapy-activated NBTXR3, giving it the opportunity for priority review and accelerated approval.

Laurent Levy is co-founder of Nanobiotix and chair of its executive board. “The enrollment of the first patient into our global Phase III study is an example of the unwavering commitment of our investigators and strategic partners,” he said.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from relying on data including charts, buy/sell signals, and quotes. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]